2.53BMarket Cap-16280P/E (TTM)
2.010High1.940Low1.17MVolume1.970Open2.000Pre Close2.29MTurnover0.09%Turnover RatioLossP/E (Static)1.28BShares2.95052wk High4.94P/B2.53BFloat Cap0.80052wk Low--Dividend TTM1.28BShs Float19.120Historical High--Dividend LFY3.50%Amplitude0.800Historical Low1.966Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
CSTONE PHARMA-B Stock Forum
December 22, 2023
2142.HK
1.56
(-2.5%)
The biopharma company has marked out a path to profitability by licensing its drug expertise and antibody platforms to partners such as Pfizer
Key Takeaways:
Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05 billion
HBM Holdin...
Clinical approvals continue to be obtained. That's not good for the market. It becomes a bad day. That means the company will continue to burn cash. After entering shenzhen-Hong Kong stock connect, trading volume is even more depressed. Cornerstones become stepping stones. There was no agency to recommend it. Share prices have given up all this year's gains. This is cstone's darkest hour.
Transaction
let go too early!
loading...
No comment yet